Pluristem Therapeutics Inc (PSTI)

[zzaatt]

having a tough time seeing what the hope is for PSTI going forward

That is the question of the day! Obviously this is a very disappointing outcome. But, I have the following thoughts:

1. Does the huge knowledge base that this company amassed have value in moving other indications thru the clinic.

2. Is the infrastructure and distribution methodology have value to other potential indication AND perhaps as a value for partnerships. After all, Pluristem has the most efficient, patented bioreactor technology.

3. Pluristem has a huge patent portfolio, is that significant value (for partnership or a buyout).

4. Do current clinical trials have a possibility for successful completion.

I think the answer is yes to all of the above.

My assessment has always been based on the question of whether stem cell technology is a viable approach, and that is still a resounding yes. The next obvious question is whether Pluristem will be the first one to succeed in delivering on the promise. The CLI result certainly sets THAT notion back, but I believe that in spite of this setback, there is still value in the company, with significant potential, albeit somewhat delayed.

If I knew the CLI outcome in advance (which is impossible) I would have sold yesterday and rebought today. Given that I did not, and that whatever immediate value loss has already taken place, I'm hanging in there, I don't think there's much near term danger of further loss.

I think this company has a greater depth than just CLI, so as for myself, I'm sticking around.